Home/Filings/4/0000950170-24-099296
4//SEC Filing

Rubin Jami 4

Accession 0000950170-24-099296

CIK 0001782303other

Filed

Aug 19, 8:00 PM ET

Accepted

Aug 20, 7:03 PM ET

Size

17.0 KB

Accession

0000950170-24-099296

Insider Transaction Report

Form 4
Period: 2024-08-19
Rubin Jami
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Stock Option

    2024-08-19196,6660 total
    Exercise: $4.10Exp: 2033-07-25Common Stock (196,666 underlying)
  • Award

    Stock Option

    2024-08-19+196,666196,666 total
    Exercise: $3.56Exp: 2033-07-25Common Stock (196,666 underlying)
  • Disposition to Issuer

    Stock Option

    2024-08-1951,4200 total
    Exercise: $8.19Exp: 2034-02-14Common Stock (51,420 underlying)
  • Disposition to Issuer

    Stock Option

    2024-08-1932,4680 total
    Exercise: $16.00Exp: 2034-03-26Common Stock (32,468 underlying)
  • Award

    Stock Option

    2024-08-19+51,42051,420 total
    Exercise: $3.56Exp: 2034-02-14Common Stock (51,420 underlying)
  • Award

    Stock Option

    2024-08-19+32,46832,468 total
    Exercise: $3.56Exp: 2034-03-26Common Stock (32,468 underlying)
Footnotes (5)
  • [F1]The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024.
  • [F2]On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged.
  • [F3]The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.
  • [F4]The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024.
  • [F5]The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability.

Documents

1 file

Issuer

Boundless Bio, Inc.

CIK 0001782303

Entity typeother

Related Parties

1
  • filerCIK 0001816484

Filing Metadata

Form type
4
Filed
Aug 19, 8:00 PM ET
Accepted
Aug 20, 7:03 PM ET
Size
17.0 KB